Genentech unveils OS benefit for Perjeta combo

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) presented Phase III data showing that Perjeta pertuzumab in combination with Herceptin trastuzumab and docetaxel chemotherapy increased the overall survival (OS) of patients with previously untreated HER2-positive metastatic breast cancer (MBC) by 15.7 months compared to Herceptin plus chemotherapy.

The combination of Perjeta plus Herceptin and chemotherapy had already met the primary endpoint of progression-free survival (PFS) compared to Herceptin plus chemotherapy, and has been approved in the U.S. and EU in these patients. ...